Items where authors include "Bliss, J.M."
Article
Ring, A. orcid.org/0000-0003-1230-2973, Kilburn, L.S. orcid.org/0000-0002-1987-7545, Pearson, A. orcid.org/0000-0002-5854-193X et al. (21 more authors) (2023) Olaparib and ceralasertib (AZD6738) in patients with triple-negative advanced breast cancer: Results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432
Velikova, G. orcid.org/0000-0003-1899-5942, Morden, J.P., Haviland, J.S. et al. (14 more authors) (2023) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology. ISSN 1470-2045
Tutt, A., Tovey, H., Cheang, M.C.U. et al. (35 more authors) (2018) Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature Medicine, 24 (5). pp. 628-637. ISSN 1078-8956
Cameron, D., Morden, J.P., Canney, P. et al. (21 more authors) (2017) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 18 (7). pp. 929-945. ISSN 1470-2045